- Home
- EXEL vs PSO Comparison
EXEL vs PSO Comparison
Compare EXEL & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | PSO |
|---|---|---|
| Founded | 1994 | 1844 |
| Country | United States | United Kingdom |
| Employees | N/A | 17116 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 8.9B |
| IPO Year | 2000 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EXEL | PSO |
|---|---|---|
| Price | $43.88 | $14.04 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $45.18 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 652.8K |
| Earning Date | 02-10-2026 | 03-03-2026 |
| Dividend Yield | N/A | ★ 2.32% |
| EPS Growth | ★ 53.55 | 31.65 |
| EPS | ★ 2.38 | 0.90 |
| Revenue | $2,288,218,000.00 | ★ $4,822,578,436.00 |
| Revenue This Year | $9.79 | $2.36 |
| Revenue Next Year | $12.01 | $5.20 |
| P/E Ratio | $18.44 | ★ $14.87 |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $31.90 | $12.85 |
| 52 Week High | $49.62 | $17.90 |
Technical Indicators
Market Signals| Indicator | EXEL | PSO |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 58.94 |
| Support Level | $40.83 | $14.05 |
| Resistance Level | $47.24 | $14.23 |
| Average True Range (ATR) | 1.11 | 0.12 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 48.94 | 47.95 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.